This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2022 Oct 20;387(16):1529-1530.

doi: 10.1056/NEJMc2211623.

Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes

Yuki Senoo¹, Masahiro Kami¹

Affiliations

PMID: 36260804
DOI: 10.1056/NEJMc2211623

Comment

Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes

Yuki Senoo et al. N Engl J Med. 2022.

. 2022 Oct 20;387(16):1529-1530.

doi: 10.1056/NEJMc2211623.

Authors

Yuki Senoo¹, Masahiro Kami¹

Affiliation

¹ Medical Governance Research Institute, Tokyo, Japan senooyuki0821@gmail.com.

PMID: 36260804
DOI: 10.1056/NEJMc2211623

No abstract available

PubMed Disclaimer

Comment in

Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes. Reply.
Arslanian SA, Cox D. Arslanian SA, et al. N Engl J Med. 2022 Oct 20;387(16):1530-1531. doi: 10.1056/NEJMc2211623. N Engl J Med. 2022. PMID: 36260805 No abstract available.

Comment on

Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.
Arslanian SA, Hannon T, Zeitler P, Chao LC, Boucher-Berry C, Barrientos-Pérez M, Bismuth E, Dib S, Cho JI, Cox D; AWARD-PEDS Investigators. Arslanian SA, et al. N Engl J Med. 2022 Aug 4;387(5):433-443. doi: 10.1056/NEJMoa2204601. Epub 2022 Jun 4. N Engl J Med. 2022. PMID: 35658022 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information